Login to Your Account



Treating the 90 Percent

Biotechs Set Their Sights on Dry AMD Treatments

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, July 30, 2012

Regeneron Pharmaceuticals Inc. stormed onto the wet age-related macular degeneration (AMD) market with second quarter sales of Eylea (aflibercept injection) increasing 57 percent compared to their first quarter. The drug competes with Roche AG's Lucentis (ranibizumab) and off-label use from Avastin (bevacizumab).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription